USE OF TOLL-LIKE RECEPTOR AGONIST FOR TREATING CANCER
The present invention is directed to methods and agents used for treating cancer in Toll-Like Receptor 5-expressing tissues by providing a Toll-Like Receptor agonist such as flagellin. The present invention also relates to protecting the liver from a liver toxicity using a Toll-like receptor agonist.
1 .- 25 . (canceled)
26 . A method of protecting liver tissue in a mammal from a liver toxicity, comprising administering an effective amount of a Toll-Like Receptor (TLR) agonist to a mammal in need thereof.
27 .- 31 . (canceled)
32 . The method of claim 26 , wherein the liver toxicity is mediated by a death receptor signaling agonist.
33 . The method of claim 32 , wherein the death receptor signaling agonist is selected from FAS, TRAIL, and TNFα.
34 . The method of claim 26 , wherein the liver toxicity is mediated by an activator of FAS-mediated apoptosis.
35 . The method of claim 26 , wherein the liver toxicity is mediated by one or more of a FAS ligand, a FAS agonistic antibody, acetaminophen, alcohol, a viral infection of the liver, and a chemotherapeutic agent.
36 . The method of claim 26 , wherein the TLR agonist is a flagellin.
37 . The method of claim 26 , wherein the TLR agonist is a flagellin derivative.
38 . The method of claim 26 , wherein the TLR agonist comprises the amino acid sequence of SEQ ID NO: 8.
39 . The method of claim 26 , wherein the TLR5 agonist is administered as a monotherapy.